Since many cells cannot take up exogenous aspartate due to no or low expression of the aspartate transporter, SLC1A3 [50], we also expressed SLC1A3 prior to aspartate supplementation to levels comparable to MDA-MB-468 breast cancer cells (S4C Fig) [54]. This evidence concerns the gene SLC1A3 and breast carcinoma.